Amicus Therapeutics, Inc. (NASDAQ: FOLD) reported Q3 EPS of ($0.31), $0.07 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $5.8 million versus the consensus estimate of $8.82 million.

For earnings history and earnings-related data on Amicus Therapeutics, Inc. (FOLD) click here.

Earnings